Cancer and Leukemia Group B

Cancer and Leukemia Group B was a cooperative clinical trials group focused on adult hematologic malignancies and solid tumors. It conducted multicenter randomized trials, developed treatment standards, and produced translational research linking laboratory discoveries to patient care. The group operated within the framework of United States federal research initiatives and subsequently merged into a larger consortium to continue its mission.

History

Founded in 1956 during a period of expansion of National Institutes of Health initiatives, the group emerged alongside contemporaries such as Southwest Oncology Group, Eastern Cooperative Oncology Group, and North Central Cancer Treatment Group. Early leadership included investigators affiliated with Mayo Clinic, Dana–Farber Cancer Institute, and Johns Hopkins Hospital, and the group responded to breakthroughs reported at meetings like the American Society of Clinical Oncology and the American Association for Cancer Research annual conferences. Throughout the 1960s and 1970s CALGB conducted trials informed by discoveries from laboratories at National Cancer Institute, University of Texas MD Anderson Cancer Center, and Fred Hutchinson Cancer Research Center. Landmark trials aligned temporally with developments such as the approval of agents by the Food and Drug Administration and conceptual advances presented at symposia in Washington, D.C. and Boston, Massachusetts. In the 1980s and 1990s CALGB expanded translational programs, collaborating with centers like Memorial Sloan Kettering Cancer Center, University of Michigan, and Stanford University School of Medicine. Regulatory interactions with Centers for Medicare & Medicaid Services and funding cycles from National Cancer Institute shaped operations until the 2014 integration into a new alliance formed with groups including American College of Surgeons-affiliated networks.

Organization and Governance

The group was governed by committees reflecting expertise from institutions such as Columbia University, Yale University, and University of Pennsylvania. Executive structures included an elected Chair, scientific advisory boards, and protocol committees with members from Cleveland Clinic, Brigham and Women's Hospital, and University of California, San Francisco. Data management and biostatistics units operated with collaborators at Johns Hopkins Bloomberg School of Public Health and Harvard Medical School. Institutional review and compliance drew upon standards set by bodies like the Office for Human Research Protections and interactions with the Food and Drug Administration. Funding oversight involved the National Institutes of Health and program officers from the National Cancer Institute Division of Cancer Treatment and Diagnosis.

Research Programs and Clinical Trials

CALGB ran randomized trials spanning lung cancer, breast cancer, colorectal cancer, leukemia, lymphoma, and myeloma in partnership with centers including University of Chicago, Duke University, and University of California, Los Angeles. Protocol development often referenced molecular findings from Cold Spring Harbor Laboratory and pharmacologic research from Eli Lilly and Company and Bristol-Myers Squibb. Trials addressed chemotherapy regimens, radiation strategies, and supportive care topics debated at forums like the European Society for Medical Oncology congress. Biostatistical design incorporated methods popularized by statisticians at University of Washington and Princeton University. Patient-reported outcomes and quality-of-life substudies invoked measures developed at RAND Corporation and coordinated with registries such as those run by Surveillance, Epidemiology, and End Results Program.

Major Scientific Contributions

The group contributed to standards in adjuvant therapy informed by evidence contemporaneous with reports from National Surgical Adjuvant Breast and Bowel Project and Intergroup Trial collaborations. CALGB investigators published pivotal results on combination chemotherapy for acute myeloid leukemia and on chemotherapy sequencing for non-small cell lung cancer that influenced practice guidelines from American Society of Clinical Oncology and National Comprehensive Cancer Network. Translational studies tied genomic markers identified at Broad Institute and Sanger Institute to clinical outcomes. Quality-of-life and survivorship research paralleled work from Moffitt Cancer Center and University of North Carolina Lineberger Comprehensive Cancer Center. Statistical methodologies advanced in cooperation with teams at University of California, Berkeley and Columbia University Mailman School of Public Health.

Collaborations and Partnerships

CALGB partnered with cooperative groups such as Cancer and Leukemia Group B-era peers, academic centers including Northwestern University, and industry sponsors like Pfizer and Novartis for investigator-initiated and industry-supported trials. International collaborations involved sites in Canada, United Kingdom, and Australia, aligning with networks like European Organisation for Research and Treatment of Cancer. Biobanking and correlative science linked CALGB to repositories at International Cancer Genome Consortium-affiliated institutions and to consortia including The Cancer Genome Atlas. Education and training collaborations included exchanges with National Institutes of Health Clinical Center and fellowships supported through American Board of Internal Medicine pathways.

Legacy and Transition (including integration into Alliance for Clinical Trials in Oncology)

CALGB's legacy includes clinical protocols that became standards of care, data resources used in meta-analyses at Cochrane Collaboration, and trained investigators who moved to leadership posts at University of Pennsylvania Perelman School of Medicine and Vanderbilt University Medical Center. In 2014 CALGB joined other cooperative groups to form a consolidated network that integrated infrastructures and regulatory frameworks, aligning with entities such as Alliance for Clinical Trials in Oncology, Institute of Medicine recommendations, and the strategic priorities of the National Cancer Institute. The transition preserved trial portfolios and biospecimen collections while enabling broader multinational partnerships with organizations including World Health Organization and regulatory harmonization consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Category:Oncology